Loading clinical trials...
Loading clinical trials...
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Conditions
Interventions
BMS-936558
Dacarbazine
+2 more
Locations
95
United States
Mayo Clinic
Phoenix, Arizona, United States
UCSD Moores Cancer Center
La Jolla, California, United States
The Angeles Clinic & Research Institute
Los Angeles, California, United States
University Of California - Los Angeles
Los Angeles, California, United States
San Francisco Oncology Associates
San Francciso, California, United States
UCSF Comprehensive Cancer Center
San Francisco, California, United States
Start Date
December 21, 2012
Primary Completion Date
February 16, 2016
Completion Date
December 29, 2020
Last Updated
April 19, 2022
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions